Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03100630 · ClinicalTrials.gov registry record · Phase 1
Compare Bioavailability of RO7239361 After Subcutaneous Injection
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 99
- Enrollment target
NCT03100630 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 99 participants.
The verdict
NCT03100630, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 99 participants
- Enrollment target
Study Summary
Randomized study in healthy men and women. Assess the similarity of RO7239361 when injected into the arm, thigh, or the stomach. Collect data on safety of RO7239361.
Interventions
- DRUG RO7239361
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2017-05-09 |
| Est. Completion | 2017-10-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03100630
The ClinicalTrials.gov registry entry for NCT03100630 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RO7239361 is the first listed.
NCT03100630 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03100630 about?
NCT03100630 is a clinical study titled "Compare Bioavailability of RO7239361 After Subcutaneous Injection". Randomized study in healthy men and women. Assess the similarity of RO7239361 when injected into the arm, thigh, or the stomach. Collect data on safety of RO7239361.
What is the current status of trial NCT03100630?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 99 participants. The study started on 2017-05-09. Estimated completion is 2017-10-17.
What interventions are being tested in trial NCT03100630?
The interventions under investigation include: RO7239361 (DRUG).
Who is sponsoring clinical trial NCT03100630?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.